Kivonat:
Abdominal obesity is referred for as a common pathogenic root of
multiple risk factors, which include insulin resistance,
dyslipidemia, hypertension, and a pro-atherogenic and pro-
inflammatory state. Irrespective of its psychiatric side
effects, rimonabant through blocking cannabinoid-1 receptor
(CB1R) induces an increase in whole body insulin sensitivity.
The aim of this work was to study the effect of selected doses
of another insulin sensitizer compound BGP-15, and rimonabant on
insulin resistance in Zucker obese rats with a promise of
inducing insulin sensitization together at lower doses than
would have been expected by rimonabant alone. We found that BGP-
15 potentiates the insulin sensitizing effect of rimonabant. The
combination at doses, which do not induce insulin sensitization
by themselves, improved insulin signaling. Furthermore our
results suggest that capsaicin-induced signal may play a role in
insulin sensitizing effect of both molecules. Our data might
indicate that a lower dose of rimonabant in the treatment of
insulin resistance and type 2 diabetes is sufficient to
administer, thus a lower incidence of the unfavorable
psychiatric side effects of rimonabant are to be expected.